August 22, 2023

Dear Colleague:

This letter is to make you aware of: 1) a new Menveo® (quadrivalent meningococcal conjugate vaccine [MenACWY (GSK)]) formulation; and 2) new childhood indications for pneumococcal 20-valent conjugate vaccine (PCV-20 [Prevnar 20® (Pfizer)]).

**New Formulation of Menveo**

Menveo will soon be available in a 1-vial presentation that does not require reconstitution. The new 1-vial presentation is approved for persons aged 10 through 55 years, while approval of the existing 2-vial presentation remains at persons 2 months through 55 years. The 1-vial presentation will have a pink cap and come in a 10-pack (vs. the orange cap for the lyophilized component of the 2-vial presentation, which comes in a 5-pack).

While both Menveo products will be available to support vaccination for children as young as 2 months of age, the existing presentation (Menveo 2-vial) will be available only in limited amounts once Menveo 1-vial becomes available. It will therefore be important to target Menveo 2-vial for use in children aged 2 months through 2 years of age, as this product is the only meningococcal conjugate vaccine approved for use in this age group (the other quadrivalent meningococcal conjugate vaccine, MenQuadfi® (Sanofi), is approved for use in those 2 years of age and older).

**PCV20 for children**

A product newly indicated for children is PCV20, the vaccine that contains capsular polysaccharide conjugates for the 13 serotypes that are in PCV13, plus an additional seven serotypes (8, 10A, 11A, 12F, 15B, 22F, and 33F). Pfizer will be replacing its Prevnar 13® with Prevnar 20. Note that the other conjugate pneumococcal vaccine, PCV15 (VAXNEUVANCE™ [Merck]) will still be available and can still be used in accordance with the following recommendations:

1. **Routine use:** Children ages 2-23 months should get either PCV15 or PCV20 according to the current recommended dosing and schedules.

2. **Catch-up vaccination:** Healthy children ages 24-59 months with incomplete PCV vaccination status and children ages 24-71 months with certain underlying conditions* and an incomplete PCV vaccination status should receive either PCV15 or PCV20 according to currently recommended dosing and schedules.

3. **Children ages 2-18 years with any risk condition** who have received all recommended doses before age 6 years do not need additional doses if they have received at least one dose of PCV20. If they received PCV13 or PCV15 but not PCV20, they should receive a dose of PCV20 or pneumococcal polysaccharide vaccine (PPSV23) using the previously recommended doses and schedule.

4. **Children ages 6-18 years with any risk condition** who have not received any dose of PCV13, PCV15 or PCV20 should receive a single dose of PCV15 or PCV20. When PCV15 is used, it should be followed by a dose of PPSV23 at least eight weeks later if not previously given.

*Risk conditions include: cerebrospinal fluid leak; chronic heart disease; chronic kidney disease (excluding maintenance dialysis and nephrotic syndrome, which are included in immunocompromising conditions); chronic liver disease; chronic lung disease (including moderate persistent or severe persistent asthma); cochlear implant; diabetes mellitus; immunocompromising conditions (on maintenance dialysis or with nephrotic syndrome; congenital or acquired asplenia or splenic dysfunction; congenital or acquired immunodeficiencies; diseases and conditions treated with immunosuppressive drugs or radiation therapy, including malignant neoplasms, leukemias, lymphomas, Hodgkin disease, and solid organ transplant; HIV infection; and sickle cell disease and other hemoglobinopathies).
The new Menveo 1-vial formulation, as well as PCV20, will be available via the Vaccine for Children (VFC) program for provider orders beginning September 1, 2023. They are both currently available in the private sector.

For questions on Menveo, Prevnar 20, or any other immunization issue, please call (347) 396-2400 or email nycimmunize@health.nyc.gov. We thank you for your continuing efforts at protecting NYC residents from vaccine-preventable illnesses.

Sincerely,

Bindy Crouch, MD, MPH
Assistant Commissioner
Bureau of Immunization